LEADER 03857nam 2200769Ia 450 001 9910810579703321 005 20200520144314.0 010 $a1-139-20910-8 010 $a1-107-22347-4 010 $a1-280-48477-2 010 $a9786613579751 010 $a1-139-22181-7 010 $a1-139-21699-6 010 $a1-139-22352-6 010 $a1-139-21392-X 010 $a1-139-22009-8 010 $a1-139-02692-5 035 $a(CKB)2670000000131847 035 $a(EBL)833378 035 $a(OCoLC)775869725 035 $a(SSID)ssj0000572812 035 $a(PQKBManifestationID)11364731 035 $a(PQKBTitleCode)TC0000572812 035 $a(PQKBWorkID)10541034 035 $a(PQKB)10250166 035 $a(UkCbUP)CR9781139026925 035 $a(Au-PeEL)EBL833378 035 $a(CaPaEBR)ebr10533290 035 $a(CaONFJC)MIL357975 035 $a(MiAaPQ)EBC833378 035 $a(PPN)261332244 035 $a(EXLCZ)992670000000131847 100 $a20110511d2012 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aXenotransplantation and risk $eregulating a developing biotechnology /$fSara Fovargue 205 $a1st ed. 210 $aCambridge ;$aNew York $cCambridge University Press$d2012 215 $a1 online resource (xiii, 291 pages) $cdigital, PDF file(s) 225 1 $aCambridge law, medicine, and ethics 300 $aTitle from publisher's bibliographic system (viewed on 05 Oct 2015). 311 $a0-521-19576-4 320 $aIncludes bibliographical references and index. 327 $aIntroducing the issues -- Dealing with risk -- Regulating experimental procedures and medical research -- Regulatory responses to developing biotechnologies -- Challenges to legal and ethical norms : first party consent and third parties at risk -- Surveillance and monitoring : balancing public health and individual freedom -- Summary and concluding thoughts : looking to the future. 330 $aSome developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These trans-boundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health. 410 0$aCambridge law, medicine, and ethics. 606 $aXenografts 606 $aTransplantation immunology 606 $aXenografts$xMoral and ethical aspects 606 $aTransplantation of organs, tissues, etc 615 0$aXenografts. 615 0$aTransplantation immunology. 615 0$aXenografts$xMoral and ethical aspects. 615 0$aTransplantation of organs, tissues, etc. 676 $a344.04/194 686 $aLAW093000$2bisacsh 700 $aFovargue$b Sara$f1971-$01052865 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910810579703321 996 $aXenotransplantation and risk$93981398 997 $aUNINA